Reference pricing of pharmaceuticals

Journal of Health Economics

Volumn 26, Issue 3, 2007, Pages 613-642

  Brekke, Kurt R ^a   Königbauer, Ingrid ^b   Straume, Odd Rune ^c,d  

^a NORWEGIAN SCHOOL OF ECONOMICS   (Norway)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MINHO   (Portugal)

^d Health Economics Bergen (HEB)   (Norway)

Author keywords

Pharmaceuticals; Product differentiation; Reference Pricing

Indexed keywords

GENERIC DRUG; NEW DRUG;

COMPETITION (ECONOMICS); DRUG; HEALTH EXPENDITURE; HEALTH RISK; INTELLECTUAL PROPERTY RIGHTS; PRICE DYNAMICS; PROFITABILITY;

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG QUALITY; MODEL; PATENT; PROFIT;

COSTS AND COST ANALYSIS; DECISION MAKING, ORGANIZATIONAL; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; EUROPE; MODELS, ECONOMETRIC; PATENTS; PHARMACEUTICAL PREPARATIONS;

EID: 34147105590     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2006.11.003     Document Type: Article

References (29)

1. Aronsson T., Bergman M.A., and Rudholm N. The impact of generic drug competition on brand name market shares - evidence from micro data. Review of Industrial Organization 19 (2001) 425-435
2. Bergman M.A., and Rudholm N. The relative importance of actual and potential competition: empirical evidence from the pharmaceuticals market. Journal of Industrial Economics LI (2003) 455-467
3. Brekke K.R., Nuscheler R., and Straume O.R. Quality and location choices under price regulation. Journal of Economics and Management Strategy 15 (2006) 207-227
4. Brekke K.R., Grasdal A., and Holmås T.H. Regulation and the pricing of pharmaceuticals: reference pricing or price cap regulation? (2006), Norwegian School of Economics & Business Adm, Mimeo
5. Cabrales, A., 2003. Pharmaceutical generics, vertical product differentiation, and public policy. Working Paper Ref. 662, Universitat Pompeu Fabra.
6. Danzon P.M. Pharmaceutical Price Regulation: National Policies versus Global Interests (1997), American Enterprise Institute Press, Washington
7. Danzon P.M. Reference Pricing: Theory and Evidence. In: Lopez-Casasnovas G., and Jönsson B. (Eds). Reference Pricing and Pharmaceutical Policy: Perspectives on Economics and Innovation (2001), Springer, Barcelona (Chapter 5)
8. Danzon P.M., and Ketcham J.D. Reference pricing of pharmaceuticals for Medicare: Evidence from Germany, The Netherlands and New Zealand. In: Cutler D., and Garber M. (Eds). Frontiers in Health Policy Research vol. 7 (2004), National Bureau of Economic Research and MIT Press
9. Danzon, P.M., Lui, H., 1996. RP and physician drug budgets: the German experience in controlling pharmaceutical expenditures. Working paper, The Wharton School.
10. Economides N. Quality variations and maximal variety differentiation. Regional Science and Urban Economics 19 (1989) 21-29
11. Frank R.G., and Salkever D.S. Generic entry and the market for pharmaceuticals. Journal of Economics & Management Strategy 6 (1997) 75-90
12. Gabszewicz J.J., and Thisse J.F. Price competition, quality and income disparities. Journal of Economic Theory 20 (1979) 340-359
13. Gabszewicz J.J., and Thisse J.F. Entry (and exit) in a differentiated industry. Economic Journal 96 (1980) 160-172
14. Grabowski H.G., and Vernon J. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 35 (1992) 331-350
15. Hellerstein J.K. The importance of the physician in the generic versus trade-name prescription decision. RAND Journal of Economics 29 (1998) 108-136
16. Hotelling H. Stability in competition. Economic Journal 39 (1929) 41-57
17. Huskamp H.A., Rosenthal M.B., Frank R.G., and Newhouse J.P. The Medicare prescription drug program: How will the game be played?. Health Affairs 19 2 (2000) 18-23
18. Kanavos, P., 2001. Overview of pharmaceutical pricing and reimbursement regulation in Europe. Commission Of The European Communities, Dg Enterprise, November.
19. Kanavos P., and Reinhardt U. Reference pricing for drugs: Is it compatible with U.S. health care. Health Affairs 22 3 (2003) 16-30
20. Königbauer I. Advertising and generic market entry. Journal of Health Economics. Health Economics 26 2 (2007) 286-305
21. Lopez-Casasnovas G., and Puig-Junoy J. Review of the Literature on Reference Pricing. Health Policy 54 (2000) 87-123
22. Ma C.-T.A., and Burgess Jr. J.F. Quality competition, welfare, and regulation. Journal of Economics 58 2 (1993) 153-173
23. Merino-Castelló, A., 2003. Impact of the reference price system on the pharmaceutical market: a theoretical approach. Working Paper Ref. 524, Universitat Pompeu Fabra.
24. Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?. RAND Journal of Economics 33 3 (2002) 469-487
25. Scherer F.M. Pricing, profits and technological progress in the pharmaceutical industry. Journal of Economic Perspectives 7 (1993) 97-115
26. Scott Morton F.M. Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. International Journal of Industrial Organization 18 (2000) 1085-1104
27. Shaked A., and Sutton J. Relaxing price competition through product differentiation. Review of Economic Studies 49 (1982) 3-13
28. Shaked A., and Sutton J. Natural oligopolies. Econometrica 51 5 (1983) 1469-1483
29. Zweifel P., and Crivelly L. Price regulation of drugs: Lessons from Germany. Journal of Regulatory Economics 10 (1996) 257-273